Clinical Trial: Open Label, Phase 2 Study of CD19t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma.

U.S., Aug. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07125872) titled 'Open Label, Phase 2 Study of CD19t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma.' on Aug. 11.

Brief Summary: Open Label, Phase 2 Study of CD19t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.

Study Start Date: Aug. 19

Study Type: INTERVENTIONAL

Condition: Relapsed B-Cell Non Hodgkin Lymphoma

Intervention: BIOLOGICAL: CD19 t-haNK- IV Administration

N-803 Subcutaneous (SQ): N-803 is a novel IL-15 superagonist immunotherapy administered...